MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- DIVIS LABORATORIES - TEVA PHARMA (Israel)
DIVIS LABORATORIES vs TEVA PHARMA (Israel) - Comparison Results
DIVIS LABORATORIES Change
Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 DIVIS LABORATORIES  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DIVIS LABORATORIES Mar-19 |
TEVA PHARMA Dec-13 |
DIVIS LABORATORIES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,639 | 3,048 | - | |
| Low | Rs | 1,115 | 2,648 | - | |
| Sales per share (Unadj.) | Rs | 186.3 | 1,749.4 | - | |
| Earnings per share (Unadj.) | Rs | 51.0 | 109.3 | - | |
| Cash flow per share (Unadj.) | Rs | 57.3 | 250.7 | - | |
| Dividends per share (Unadj.) | Rs | 16.00 | 95.67 | - | |
| Dividend yield (eoy) | % | 1.2 | 3.4 | 34.6% | |
| Book value per share (Unadj.) | Rs | 261.8 | 1,943.3 | - | |
| Shares outstanding (eoy) | m | 265.47 | 848.00 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 7.4 | 1.6 | 454.0% | |
| Avg P/E ratio | x | 27.0 | 26.1 | 103.7% | |
| P/CF ratio (eoy) | x | 24.0 | 11.4 | 211.5% | |
| Price / Book Value ratio | x | 5.3 | 1.5 | 358.9% | |
| Dividend payout | % | 31.4 | 87.5 | 35.9% | |
| Avg Mkt Cap | Rs m | 365,592 | 2,415,248 | 15.1% | |
| No. of employees | `000 | 11.8 | 44.9 | 26.4% | |
| Total wages/salary | Rs m | 5,423 | 0 | - | |
| Avg. sales/employee | Rs Th | 4,175.1 | 33,007.7 | 12.6% | |
| Avg. wages/employee | Rs Th | 457.7 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,141.8 | 2,062.0 | 55.4% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 49,463 | 1,483,531 | 3.3% | |
| Other income | Rs m | 1,556 | 0 | - | |
| Total revenues | Rs m | 51,019 | 1,483,531 | 3.4% | |
| Gross profit | Rs m | 18,718 | 406,266 | 4.6% | |
| Depreciation | Rs m | 1,689 | 119,915 | 1.4% | |
| Interest | Rs m | 35 | 29,139 | 0.1% | |
| Profit before tax | Rs m | 18,551 | 257,212 | 7.2% | |
| Minority Interest | Rs m | 0 | 1,168 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -168,845 | 0.0% | |
| Tax | Rs m | 5,023 | -3,140 | -160.0% | |
| Profit after tax | Rs m | 13,527 | 92,675 | 14.6% | |
| Gross profit margin | % | 37.8 | 27.4 | 138.2% | |
| Effective tax rate | % | 27.1 | -1.2 | -2,217.9% | |
| Net profit margin | % | 27.3 | 6.2 | 437.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 46,501 | 1,001,972 | 4.6% | |
| Current liabilities | Rs m | 8,468 | 873,804 | 1.0% | |
| Net working cap to sales | % | 76.9 | 8.6 | 890.0% | |
| Current ratio | x | 5.5 | 1.1 | 478.9% | |
| Inventory Days | Days | 131 | 91 | 144.1% | |
| Debtors Days | Days | 86 | 96 | 89.5% | |
| Net fixed assets | Rs m | 25,797 | 484,554 | 5.3% | |
| Share capital | Rs m | 531 | 3,652 | 14.5% | |
| Net worth | Rs m | 69,493 | 1,647,922 | 4.2% | |
| Long term debt | Rs m | 0 | 758,563 | 0.0% | |
| Total assets | Rs m | 80,383 | 3,390,345 | 2.4% | |
| Interest coverage | x | 531.0 | 9.8 | 5,403.6% | |
| Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
| Sales to assets ratio | x | 0.6 | 0.4 | 140.6% | |
| Return on assets | % | 16.9 | 3.6 | 469.6% | |
| Return on equity | % | 19.5 | 5.6 | 346.1% | |
| Return on capital | % | 26.7 | 4.9 | 542.3% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 9,543 | 236,398 | 4.0% | |
| From Investments | Rs m | -6,854 | -83,765 | 8.2% | |
| From Financial Activity | Rs m | -2,459 | -283,575 | 0.9% | |
| Net Cashflow | Rs m | 230 | -130,943 | -0.2% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 73.03 Rs / USD
Compare DIVIS LABORATORIES With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare DIVIS LABORATORIES With: ALKEM LABORATORIES TORRENT PHARMA PANACEA BIOTECH WOCKHARDT BIOCON
Today's Market
Crucial Week Ahead for the Indian Stock Market(Momentum Moves)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
Related Views On News
DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)
Aug 10, 2020 | Updated on Aug 10, 2020For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)
Jun 8, 2020 | Updated on Jun 8, 2020For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)
Oct 10, 2019 | Updated on Oct 10, 2019Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.
More Views on NewsMost Popular
Why Gold Hit Lower Circuit (Fast Profits Daily)
Jan 11, 2021Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Time to Book Profits in Pharma Stocks (Fast Profits Daily)
Jan 15, 2021In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
A Rare Chance to Invest in Potential Multibaggers in 2021 (Profit Hunter)
Jan 11, 2021Our ace stock picker is ready to capitalise on a big growth opportunity.
Smallcap Stocks: Your Best Bet for 2021 and Beyond (Profit Hunter)
Jan 15, 2021The pandemic failed to thwart Richa's investing success formula for 2020.
More
